RecruitingPhase 2NCT06727331

Study of Tirzepatide for Recovery and Alcohol Use Management

Tirzepatide for the Treatment of Alcohol Use Disorder: A Pilot Randomized Controlled Trial

Sponsor

Brigham and Women's Hospital

Enrollment

20 participants

Start Date

Sep 15, 2025

Study Type

INTERVENTIONAL

Conditions

Alcohol Use Disorder (AUD)

Summary

This is a pilot, 4-week, double-blind, placebo-controlled, randomized trial of individuals with alcohol use disorder (AUD) to receive weekly injections of either tirzepatide (n=10) or matching placebo (n=10). The primary aim is to determine the effects of tirzepatide on cue-reactivity among individuals with AUD. The secondary aim is to assess the safety and preliminary efficacy of tirzepatide for AUD.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Saline Placebo and a drug called Tirzepatide for people with alcohol use disorder (aud). The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTirzepatide

This intervention will consist of the FDA-approved dosing schedule. Participants will receive 2.5mg weekly injections for 4 weeks. IDS will extract tirzepatide and draw the doses into syringes.

OTHERSaline Placebo

Placebo syringes of saline and matching volume will be produced by IDS.